GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2023
Other intangible assets
Finite-lived intangible assets, period increase (decrease)		$ 511
Amortization of intangible assets		9,200	$ 9,700	$ 10,200
Future estimated amortization, 2024		8,700
Future estimated amortization, 2025		3,200
Future estimated amortization, 2026		1,700
Future estimated amortization, 2027		1,600
Future estimated amortization, 2028		1,600
Impairment of other intangible assets		$ 136	101	1,200
Payments to acquire intangible assets				300
Subsequent Event
Other intangible assets
Payment for contingent consideration liability	$ 400
In Process Research and Development
Other intangible assets
Identifiable assets acquired, indefinite-lived intangible assets			$ 2,800		$ 2,800
Investigational Compound for Hematologic Diseases | Celgene
Other intangible assets
Impairment of other intangible assets				610
Investigational Compound for Fibrotic Diseases | Celgene
Other intangible assets
Impairment of other intangible assets				230
Inrebic
Other intangible assets
Impairment of other intangible assets				315
Inrebic | Technology-Based Intangible Assets
Other intangible assets
Finite-lived intangible assets, net				$ 385